Major Depressive Disorder

Anti-inflammatory drugs ease anhedonia and depressive symptoms in high-CRP depression, spotlighting CRP-guided treatment and lifestyle strategies while calling for stronger RCTs.

Large meta-analysis finds GLP-1 drugs don’t raise depression or suicidality and modestly boost quality of life and eating control in diabetes/obesity.

Online tool personalizes antidepressant choice in primary care, cutting dropouts and improving 24-week depression and anxiety scores.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

FDA clears MIND1 trial testing NRX-101 plus robotic TMS to curb suicidality in treatment-resistant depression, with military-focused sites.

Explore how neuromelanin-sensitive MRI noninvasively tracks long-term dopamine and noradrenaline system changes.

New analysis ranks lumateperone top for adjunctive MDD symptom relief, with minimal weight gain vs other atypical antipsychotics.

The triple-blinded EPISODE trial with active placebo and 4 dosing regimens yielded mixed results, reflecting the challenge of discerning psilocybin effect and distinguishing between enlightenment and expectation.

New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.

Lifestyle medicine pillars help reshape depression and anxiety treatment in psychiatry.

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

In this CME article, learn how depression hides in organ failure, transplants, neurologic disease, and hormonal shifts—plus screening tips and safer treatment choices.

Deep intracranial frequency stimulation 77.5 Hz high-gamma approach was associated with statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents with nonsuicidal self-injury.

BPL-003 phase 2a part 2 results show reductions in depression symptoms.

An interview with Felice Jacka, OAM, PhD, on the rapidly developing field of nutritional psychiatry.

Intranasal BPL-003 shows rapid, sustained depression relief in treatment-resistant patients.

Data show fast-acting psychedelic therapy for depression with lasting gains—plus the safety questions shaping its future.

New serotonergic therapies show durable relief in Phase II anxiety trials, as clinicians and patients partner to tackle unmet depression needs.

Psychedelic therapies surge in trials, but safety varies by substance—learn key benefits, risks, and why psychiatric history raises complications.

FDA feedback for CYC-126: anesthetic therapy with live EEG guidance aims to deliver precise relief for treatment-resistant depression.

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

Adjunctive lithium sharply reduces relapse and suicidal ideation, and attempts in patients with bipolar disorder and major depressive disorder.

How ketamine sparks a glutamate-driven BDNF burst, reshaping prefrontal connectivity in depression and revealing the glutamate–GABA partnership.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.